Dermatology: Acne, Eczema, Psoriasis & Rosacea • ICD-10-CM L98.6
Jessner's lymphocytic infiltration of the skin
Also known as: Infiltration, Infiltrated, Infiltrates, Opacity
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM L98.6 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Priya Nair, MD, FAAD (NPI #1295730425)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Jessner's lymphocytic infiltration of the skin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Jessner's lymphocytic infiltration of the skin (also termed Infiltration or Infiltrated) is an ICD-10-CM indexed diagnosis (L98.6) within Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 2 Real-world patient consensus: Synonyms for Jessner's lymphocytic infiltration of the skin (L98.6): Infiltration, Infiltrated, Infiltrates (Skin & Dermatology).
- 3 Typical cash cost range: Clinicians assessing Jessner's lymphocytic infiltration of the skin focus on keratinocyte hyperproliferation [Jessner's lymphocytic infiltration of the skin L98.6] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Jessner's lymphocytic infiltration of the skin: 25-Hydroxy Vitamin D in Jessner's lymphocytic infiltration of the skin (L98.6: & hs-CRP) (25(OH)D 40–65 ng/mL (L98.6)) and Affected Body Surface in Jessner's lymphocytic infiltration of the skin (L98.6: Area (BSA /).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Jessner's lymphocytic infiltration of the skin
What Is Jessner's lymphocytic infiltration of the skin?
Jessner's lymphocytic infiltration of the skin (also termed Infiltration or Infiltrated) is an ICD-10-CM indexed diagnosis (L98.6) within Dermatology: Acne, Eczema, Psoriasis & Rosacea. Clinical evaluation centers on contact/systemic trigger review [Jessner's lymphocytic infiltration of the skin L98.6] alongside serial 25-Hydroxy Vitamin D in Jessner's lymphocytic infiltration of the skin (L98.6: & hs-CRP) tracking (25(OH)D 40–65 ng/mL (L98.6)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Jessner's lymphocytic infiltration of the skin (ICD-10 L98.6) is driven by keratinocyte hyperproliferation [Jessner's lymphocytic infiltration of the skin L98.6]; specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor Affected Body Surface in Jessner's lymphocytic infiltration of the skin (L98.6: Area (BSA /) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Jessner's lymphocytic infiltration of the skin (L98.6): persistent erythematous plaques, in Jessner's lymphocytic infiltration of the skin (L98.6: scaly patches, pruritic)
- • Secondary Jessner's lymphocytic infiltration of the skin clinical sign: compromised epidermal barrier in Jessner's lymphocytic infiltration of the skin (L98.6: with dryness, fissuring,)
- • Symptom flares in Jessner's lymphocytic infiltration of the skin correlating with 25-Hydroxy Vitamin D in Jessner's lymphocytic infiltration of the skin (L98.6: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L98.6)
- • Functional skin & dermatology impact requiring contact/systemic trigger review [Jessner's lymphocytic infiltration of the skin L98.6] evaluation (L98.6)
Jessner's lymphocytic infiltration of the skin Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L98.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Jessner's lymphocytic infiltration of the skin (L98.6: & hs-CRP) | 25(OH)D 40–65 ng/mL (L98.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Jessner's lymphocytic infiltration of the skin (L98.6: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L98.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Jessner's lymphocytic infiltration of the skin (L98.6: ALT (if systemic) | Within baseline reference limits (L98.6) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Jessner's lymphocytic infiltration of the skin
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lidocaine HCl and Epinephrine Lidocaine HCl and Epinephrine Generic • RxCUI RXN-516621504-3096 | alpha-Adrenergic Agonist | 89% | $0.0989 | $ 12.50 /mo |
| Bupivacaine Hydrochloride and Epinephrine Marcaine with Epinephrine • RxCUI RXN-04093812-2235 | Amide Local Anesthetic | 89% | $0.0458 | $ 10.36 /mo |
| Bupivacaine and Meloxicam Zynrelef • RxCUI RXN-47426503-2643 | Amide Local Anesthetic | 94% | $0.0458 | $ 10.36 /mo |
| Sensorcaine(R) (Bupivacaine Hci and Epinephrine) Sensorcaine(R) (Bupivacaine Hci and Epinephrine) Generic • RxCUI RXN-516621397-2360 | Amide Local Anesthetic | 86% | $1.3700 | $ 63.99 /mo |
| 1% Lidocaine Hci 1% Lidocaine Hci Generic • RxCUI RXN-516621465-2365 | Amide Local Anesthetic | 77% | $2.8500 | $ 123.93 /mo |
| 2% Lidocaine Hci 2% Lidocaine Hci Generic • RxCUI RXN-516621326-2526 | Amide Local Anesthetic | 81% | $1.1200 | $ 53.86 /mo |
| 0.25% Bupivacaine HCl 0.25% Bupivacaine HCl Generic • RxCUI RXN-516621606-2531 | Amide Local Anesthetic | 81% | $1.0000 | $ 49.00 /mo |
| 0.5% Lidocaine HCl 0.5% Lidocaine HCl Generic • RxCUI RXN-516621600-2530 | Amide Local Anesthetic | 91% | $0.3700 | $ 23.48 /mo |
| Bupivacaine Exparel • RxCUI 1191508 | Amide Local Anesthetic | 78% | $0.0458 | $ 10.36 /mo |
| Lidocaine Hydrochloride, Epinephrine Bitartrate Injection, Solution Xylocaine • RxCUI RXN-04049975-3185 | Amide Local Anesthetic | 77% | $0.0989 | $ 12.50 /mo |
| Bendamustine Hydrochloride Vivimusta, Belrapzo • RxCUI 1726097 | Alkylating Drug | 93% | $3.2500 | $ 140.13 /mo |
| Chlorambucil Leukeran • RxCUI 105553 | Alkylating Drug | 87% | $1.7800 | $ 80.59 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Jessner's lymphocytic infiltration of the skin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Improvement and maintenance of clinical outcome assessments in eczema with Amlitelimab treatment led to clinically meaningful improvements in COAs by Week 24 versus placebo. Journal of the European Academy of Dermatology and Venereology : JEADV • 2025-12-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 40704660 ↗ |
| New Insights on Tapinarof cream for the treatment of eczema: real-world benefits and safety: What a 216-Participant Study Found Across the two trials, most side effects (AEs) were mild or moderate; common AEs included folliculitis, acne, and headache. The Journal of dermatology • 2024-11-15 • Phase III Randomized Trial | N = 216 | 88/100 | PMID 39269202 ↗ |
| Can This Approach Help? Inside the Latest Research on Targeting IL-13 with tralokinumab normalizes type 2 inflammation in eczema both Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non-lesional levels, further highlighting the key role of IL-13... Allergy • 2024-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38563683 ↗ |
| New Insights on Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly: What a 521-Participant Study Found Cal/BD foam was highly efficacious and well tolerated during the 4-week lead-in phase of PSO-LONG. Journal of drugs in dermatology : JDD • 2021-04-01 • Phase III Randomized Trial | N = 521 | 87/100 | PMID 33852252 ↗ |
| Can This Approach Help? Inside the Latest Research on Simplifying regimens promotes greater staying on track with medication and Both CTG and separate applications of C gel + T cream improved mild to moderate acne. Cutis • 2010-08-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 20919606 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Jessner's lymphocytic infiltration of the skin Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Jessner's lymphocytic infiltration of the skin community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Jessner's lymphocytic infiltration of the skin.